Pubblicazioni

• Effectiveness and Safety of CGRP-mAbs in Menstrual-Related Migraine: A Real-World Experience
• Readability Analysis of Online Headache and Migraine Information
• Is the pathology of posterior cortical atrophy clinically predictable?
• Immunomodulatory effects of ocrelizumab and candidate biomarkers for monitoring treatment response in multiple sclerosis
• Systematic Review on the Role of Lobar Cerebral Microbleeds in Cognition
• Understanding and managing the impact of the Covid-19 pandemic and lockdown on patients with multiple sclerosis
• Apparently isolated CNS involvement in Erdheim-Chester disease: Case report
• Exploring Circulating Long Non-Coding RNAs in Mild Cognitive Impairment Patients' Blood
• Alemtuzumab-Related Lymphocyte Subset Dynamics and Disease Activity or Autoimmune Adverse Events: Real-World Evidence
• Predictors of Cladribine Effectiveness and Safety in Multiple Sclerosis: A Real-World, Multicenter, 2-Year Follow-Up Study
• Singular cases of Alzheimer's disease disclose new and old genetic "acquaintances"
• MicroRNA Expression Signature in Mild Cognitive Impairment Due to Alzheimer's Disease
• The Rise of the GRN C157KfsX97 Mutation in Southern Italy: Going Back to the Fall of the Western Roman Empire
• Role of Ocrelizumab in modulating gene and microRNA expression in multiple sclerosis
• MicroRNA-142-3p shuttling in extracellular vesicles marks regulatory T cell dysfunction in multiple sclerosis
• Ocrelizumab and ofatumumab comparison: an Italian real-world propensity score matched study
• Disability assessment using Google Maps
• Maternal and fetal outcomes in an Italian multicentric cohort of women with multiple sclerosis exposed to dimethyl fumarate during pregnancy
• Long-Term Effectiveness and Safety of Rituximab in Neuromyelitis Optica Spectrum Disorder: A 5-Year Observational Study
• NEDA-3 achievement in early highly active relapsing remitting multiple sclerosis patients treated with Ocrelizumab or Natalizumab
• Ocrelizumab Alters Cytotoxic Lymphocyte Function While Reducing EBV-Specific CD8+ T-Cell Proliferation in Patients With Multiple Sclerosis
• Correction to: Disability assessment using Google Maps
• Therapeutic choices and disease activity after 2 years of treatment with cladribine: An Italian multicenter study (CladStop)
• Identifying Cladribine prescription pattern in MS: an Italian multicentre study
• Breakthrough SARS-CoV-2 infections in MS patients on disease-modifying therapies
• Real-world comparison of lymphopenia profiles in S1P receptor modulators for multiple sclerosis: a multicenter retrospective study
• COVID-19 Severity in Multiple Sclerosis: Putting Data Into Context
• Signs and symptoms of COVID-19 in patients with multiple sclerosis
• A real-world study of alemtuzumab in a cohort of Italian patients
• Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis
• Multiple sclerosis and genetic polymorphisms in fibrinogen-mediated hemostatic pathways: a case-control study
• SARS-CoV-2 serology after COVID-19 in multiple sclerosis: An international cohort study
• Treatment of multiple sclerosis with rituximab: A multicentric Italian-Swiss experience
• Prognostic Markers of Ocrelizumab Effectiveness in Multiple Sclerosis: A Real World Observational Multicenter Study
• Validation of an iPad version of the Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS)
• The effect of air pollution on COVID-19 severity in a sample of patients with multiple sclerosis
• Extending the Interval of Natalizumab Dosing: Is Efficacy Preserved?
• Dimethyl fumarate vs Teriflunomide: an Italian time-to-event data analysis
• Switch from sequestering to anti-CD20 depleting treatment: disease activity outcomes during wash-out and in the first 6 months of ocrelizumab therapy
• Assessment of Multiple Sclerosis Disability Progression Using a Wearable Biosensor: A Pilot Study
• Health related quality of life in the domain of physical activity predicts confirmed disability progression in people with relapsing remitting multiple sclerosis
• Cladribine vs other drugs in MS: Merging randomized trial with real-life data
• Exit Strategies in Natalizumab-Treated RRMS at High Risk of Progressive Multifocal Leukoencephalopathy: a Multicentre Comparison Study
• Impact of COVID-19 on pregnancy and fetal outcomes in women with multiple sclerosis
• MRI activity and extended interval of Natalizumab dosing regimen: a multicentre Italian study
• Unraveling diagnostic uncertainty in transition phase from relapsing-remitting to secondary progressive multiple sclerosis
• Is It Time for Ocrelizumab Extended Interval Dosing in Relapsing Remitting MS? Evidence from An Italian Multicenter Experience During the COVID-19 Pandemic
• Determinants of therapy switch in multiple sclerosis treatment-naïve patients: A real-life study
• First therapy choice in newly diagnosed Multiple Sclerosis patients: A multicenter Italian study
• Outcomes after fingolimod to alemtuzumab treatment shift in relapsing-remitting MS patients: a multicentre cohort study
• Assessing association of comorbidities with treatment choice and persistence in MS: A real-life multicenter study
• CD19 Cell Count at Baseline Predicts B Cell Repopulation at 6 and 12 Months in Multiple Sclerosis Patients Treated with Ocrelizumab
• Sativex in resistant multiple sclerosis spasticity: Discontinuation study in a large population of Italian patients (SA.FE. study)
• Long-term effectiveness of natalizumab in secondary progressive multiple sclerosis: A propensity-matched study
• Unmet needs and gaps in the identification of secondary progression in multiple sclerosis: a Southern Italy healthcare professionals' perspective
• Ocrelizumab Extended Interval Dosing in Primary Progressive Multiple Sclerosis: An Italian Experience
• PML risk is the main factor driving the choice of discontinuing natalizumab in a large multiple sclerosis population: results from an Italian multicenter retrospective study
• Nabiximols discontinuation rate in a large population of patients with multiple sclerosis: a 18-month multicentre study
• Retrospectively acquired cohort study to evaluate the long-term impact of two different treatment strategies on disability outcomes in patients with relapsing multiple sclerosis (RE.LO.DI.MS): data from the Italian MS Register
• Cognitive performance in multiple sclerosis: the contribution of intellectual enrichment and brain MRI measures
• Assessing disability and relapses in multiple sclerosis on tele-neurology
• Plasma microRNA Signature as Predictive Marker of Clinical Response to Therapy During Multiple Sclerosis
• ChatGPT vs. neurologists: a cross-sectional study investigating preference, satisfaction ratings and perceived empathy in responses among people living with multiple sclerosis
• [The value of the MRI in defining the morfology of cerebral aging]
• Social Media and Multiple Sclerosis in the Posttruth Age
• Epidemiological and Immune Profile Analysis of Italian Subjects with Endometriosis and Multiple Sclerosis
• Sexual Dysfunction in People with Multiple Sclerosis: The Role of Disease Severity, Illness Perception, and Depression
• COVID-19 pandemic and mental distress in multiple sclerosis: Implications for clinical management
• Lesion load may predict long-term cognitive dysfunction in multiple sclerosis patients
• The Dress: Transforming a web viral event into a scientific survey
• Cognitive reserve predicts long-term cognitive trajectories in relapsing-remitting multiple sclerosis
• Physical Exercise Moderates the Effects of Disability on Depression in People with Multiple Sclerosis during the COVID-19 Outbreak
• Health-care disparities stemming from sexual orientation of Italian patients with Multiple Sclerosis: A cross-sectional web-based study